AstraZeneca (AZN) has released an update.
AstraZeneca PLC is set to acquire Fusion Pharmaceuticals in a significant move to boost its oncology portfolio with innovative radioconjugates (RCs) for cancer treatment, including a promising clinical-stage treatment for prostate cancer. The deal, valued at approximately $2 billion with additional contingent payments based on regulatory milestones, will see Fusion become a wholly owned subsidiary, enhancing AstraZeneca’s capabilities in precision cancer therapy. The acquisition is poised to transform cancer care with next-generation targeted treatments and is expected to close in the second quarter of 2024, subject to approvals.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
